CH621334A5 - - Google Patents

Download PDF

Info

Publication number: CH621334A5
Authority: CH; Switzerland
Prior art keywords: effect; compounds; micrograms; active ingredient; poly
Prior art date: 1974-04-29

Application number

CH943279A

Other languages

German (de)

English (en)

Inventor

Laszlo Feuer

Arpad Furka

Ferenc Sebestyen

Jolan Hercsel-Szepespataky

Erzsebet Bendefy-Dobay

Original Assignee

Chinoin Gyogyszer Es Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-04-29

Filing date

1979-10-19

Publication date

1981-01-30

1974-04-29 Priority claimed from HU74FE00000928A external-priority patent/HU171576B/hu

1975-03-26 Priority claimed from HU74CI1558A external-priority patent/HU174114B/hu

1979-10-19 Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet

1981-01-30 Publication of CH621334A5 publication Critical patent/CH621334A5/de

Links

150000001875 compounds Chemical class 0.000 description 25
230000000694 effects Effects 0.000 description 25
239000004480 active ingredient Substances 0.000 description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
238000002360 preparation method Methods 0.000 description 12
239000000243 solution Substances 0.000 description 8
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 8
235000019155 vitamin A Nutrition 0.000 description 8
239000011719 vitamin A Substances 0.000 description 8
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
229940045997 vitamin a Drugs 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
210000003491 skin Anatomy 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
229960003080 taurine Drugs 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000013543 active substance Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000002329 infrared spectrum Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
229920002643 polyglutamic acid Polymers 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
239000002537 cosmetic Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
150000003862 amino acid derivatives Chemical class 0.000 description 3
239000003708 ampul Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000011109 contamination Methods 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000000034 method Methods 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
-1 p-nitrophenoxy, pentachlorophenoxy Chemical group 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
239000011573 trace mineral Substances 0.000 description 3
235000013619 trace mineral Nutrition 0.000 description 3
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
201000007100 Pharyngitis Diseases 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000021386 Sjogren Syndrome Diseases 0.000 description 2
206010041591 Spinal osteoarthritis Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000003674 animal food additive Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960003151 mercaptamine Drugs 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
208000005801 spondylosis Diseases 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
RSDQBPGKMDFRHH-MJVIGCOGSA-N (3s,3as,5ar,9bs)-3,5a,9-trimethyl-3a,4,5,7,8,9b-hexahydro-3h-benzo[g][1]benzofuran-2,6-dione Chemical compound O=C([C@]1(C)CC2)CCC(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 RSDQBPGKMDFRHH-MJVIGCOGSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
241001164374 Calyx Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
208000000571 Fibrocystic breast disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
206010020914 Hypervitaminoses Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021135 Hypovitaminosis Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000001393 Lathyrism Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000006670 Multiple fractures Diseases 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
241001484645 Ozaena Species 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010048979 Sinobronchitis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
RSDQBPGKMDFRHH-UHFFFAOYSA-N Taurin Natural products C1CC2(C)C(=O)CCC(C)=C2C2C1C(C)C(=O)O2 RSDQBPGKMDFRHH-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
235000019742 Vitamins premix Nutrition 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000003973 alkyl amines Chemical group 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
208000011803 breast fibrocystic disease Diseases 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
125000001142 dicarboxylic acid group Chemical group 0.000 description 1
230000029087 digestion Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000035876 healing Effects 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940127017 oral antidiabetic Drugs 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229940056211 paraffin Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002784 sclerotic effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008786 sensory perception of smell Effects 0.000 description 1
230000014860 sensory perception of taste Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
150000003377 silicon compounds Chemical class 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
210000003781 tooth socket Anatomy 0.000 description 1
230000008359 toxicosis Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
150000002266 vitamin A derivatives Chemical class 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Birds (AREA)
Immunology (AREA)
Dermatology (AREA)
Zoology (AREA)
Virology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CH943279A 1974-04-29 1979-10-19 CH621334A5 (cs)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU74FE00000928A HU171576B (hu)	1974-04-29	1974-04-29	Sposob otdelenija gamma-l-glutamil-taurina
HU74CI1558A HU174114B (hu)	1975-03-26	1975-03-26	Sposob poluchenija novykh proizvodnykh aminokislot

Publications (1)

Publication Number	Publication Date
CH621334A5 true CH621334A5 (cs)	1981-01-30

Family

ID=26318406

Family Applications (4)

Application Number	Title	Priority Date
CH539075A CH617183A5 (cs)	1974-04-29	1975-04-28
CH943379A CH624098A5 (cs)	1974-04-29	1979-10-19
CH943179A CH621333A5 (cs)	1974-04-29	1979-10-19
CH943279A CH621334A5 (cs)	1974-04-29	1979-10-19

Family Applications Before (3)

Application Number	Title	Priority Date
CH539075A CH617183A5 (cs)	1974-04-29	1975-04-28
CH943379A CH624098A5 (cs)	1974-04-29	1979-10-19
CH943179A CH621333A5 (cs)	1974-04-29	1979-10-19

Country Status (23)

Country	Link
JP (1)	JPS6012347B2 (cs)
AR (3)	AR218222A1 (cs)
AT (6)	AT361902B (cs)
AU (1)	AU499173B2 (cs)
BE (1)	BE828546A (cs)
BG (4)	BG26369A4 (cs)
CA (1)	CA1051802A (cs)
CH (4)	CH617183A5 (cs)
CS (4)	CS209855B2 (cs)
DD (2)	DD122377A5 (cs)
DE (2)	DE2559989C3 (cs)
DK (10)	DK155433C (cs)
EG (1)	EG11847A (cs)
ES (4)	ES436986A1 (cs)
FI (1)	FI65990C (cs)
FR (1)	FR2279388A1 (cs)
GB (1)	GB1504541A (cs)
IL (1)	IL47149A (cs)
NL (1)	NL183186C (cs)
NO (2)	NO146430C (cs)
PL (2)	PL111745B1 (cs)
SE (2)	SE430164B (cs)
SU (1)	SU747419A3 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU178199B (en) *	1976-05-06	1982-03-28	Chinoin Gyogyszer Es Vegyeszet	New process for producing amides of omega-amino-carboxylic acids
HU180443B (en) *	1979-04-02	1983-03-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing a pharmaceutical preparation with synergetic action against radiation
HU185632B (en) *	1981-03-27	1985-03-28	Chinoin Gyogyszer Es Vegyeszet	New process for preparing gamma-glutamyl-taurine
CH665645A5 (fr) *	1981-07-09	1988-05-31	Michel Flork	Derives de dipeptides et leur procede de preparation.
HU208072B (en) *	1990-02-28	1993-08-30	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition suitable for preventing and curing autoimmune diseases and skin affections caused by heat and light radiacion
JPH0680964A (ja) *	1991-12-27	1994-03-22	Sogo Yatsukou Kk	活性酸素消去剤
JPH11180846A (ja) *	1997-12-15	1999-07-06	Sogo Pharmaceut Co Ltd	化粧料
DE10133197A1 (de) *	2001-07-07	2003-01-23	Beiersdorf Ag	Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
ES2533463T3 (es)	2006-10-12	2015-04-10	Bhi Limited Partnership	Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
US9662304B1 (en) *	2013-06-13	2017-05-30	Thermolife International, Llc	Substituted glutaurine compounds and substituted glutaurine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU169462B (cs) *	1971-08-04	1976-11-28

1975
- 1975-04-23 IL IL47149A patent/IL47149A/xx unknown
- 1975-04-24 AT AT314075A patent/AT361902B/de not_active IP Right Cessation
- 1975-04-24 DE DE2559989A patent/DE2559989C3/de not_active Expired
- 1975-04-24 DE DE19752518160 patent/DE2518160A1/de active Granted
- 1975-04-25 FI FI751256A patent/FI65990C/fi not_active IP Right Cessation
- 1975-04-25 ES ES436986A patent/ES436986A1/es not_active Expired
- 1975-04-25 SE SE7504828A patent/SE430164B/xx not_active IP Right Cessation
- 1975-04-28 DD DD185727A patent/DD122377A5/xx unknown
- 1975-04-28 CA CA225,659A patent/CA1051802A/en not_active Expired
- 1975-04-28 SU SU752128794A patent/SU747419A3/ru active
- 1975-04-28 CH CH539075A patent/CH617183A5/de not_active IP Right Cessation
- 1975-04-28 NO NO751504A patent/NO146430C/no unknown
- 1975-04-28 AU AU80564/75A patent/AU499173B2/en not_active Expired
- 1975-04-28 DK DK182875A patent/DK155433C/da not_active IP Right Cessation
- 1975-04-28 EG EG262/75A patent/EG11847A/xx active
- 1975-04-28 DD DD193288A patent/DD125070A5/xx unknown
- 1975-04-28 FR FR7513230A patent/FR2279388A1/fr active Granted
- 1975-04-28 GB GB17608/75A patent/GB1504541A/en not_active Expired
- 1975-04-29 PL PL1975196801A patent/PL111745B1/pl unknown
- 1975-04-29 BE BE155914A patent/BE828546A/xx not_active IP Right Cessation
- 1975-04-29 BG BG030768A patent/BG26369A4/xx unknown
- 1975-04-29 BG BG029816A patent/BG26368A3/xx unknown
- 1975-04-29 PL PL1975196798A patent/PL111746B1/pl unknown
- 1975-04-29 BG BG030770A patent/BG26370A4/xx unknown
- 1975-04-29 BG BG030769A patent/BG26517A4/xx unknown
- 1975-04-29 CS CS752987A patent/CS209855B2/cs unknown
- 1975-04-29 NL NLAANVRAGE7505075,A patent/NL183186C/xx not_active IP Right Cessation
- 1975-04-30 JP JP50051612A patent/JPS6012347B2/ja not_active Expired
1976
- 1976-04-02 AR AR262770A patent/AR218222A1/es active
- 1976-04-02 AR AR262768A patent/AR218221A1/es active
- 1976-04-02 AR AR262769A patent/AR217236A1/es active
- 1976-11-13 ES ES453304A patent/ES453304A1/es not_active Expired
- 1976-11-13 ES ES453306A patent/ES453306A1/es not_active Expired
- 1976-11-13 ES ES453305A patent/ES453305A1/es not_active Expired
1977
- 1977-08-30 AT AT624777A patent/AT359084B/de not_active Expired
- 1977-08-30 AT AT624877A patent/AT359085B/de not_active IP Right Cessation
- 1977-08-30 AT AT624977A patent/AT351007B/de not_active IP Right Cessation
- 1977-10-06 DK DK442877A patent/DK158676C/da active
- 1977-10-06 DK DK442477A patent/DK155732C/da not_active IP Right Cessation
- 1977-10-06 DK DK442677A patent/DK159654C/da not_active IP Right Cessation
- 1977-10-06 DK DK442777A patent/DK442777A/da not_active Application Discontinuation
- 1977-10-06 DK DK442377A patent/DK155520C/da not_active IP Right Cessation
- 1977-10-06 DK DK442577A patent/DK442577A/da not_active Application Discontinuation
- 1977-10-06 DK DK443077A patent/DK159267C/da not_active IP Right Cessation
- 1977-10-06 DK DK442977A patent/DK442977A/da unknown
1978
- 1978-09-22 CS CS786128A patent/CS209856B2/cs unknown
- 1978-09-22 CS CS786129A patent/CS209857B2/cs unknown
- 1978-09-22 CS CS786130A patent/CS209858B2/cs unknown
- 1978-12-14 SE SE7812884A patent/SE441356B/sv not_active IP Right Cessation
1979
- 1979-04-30 AT AT0323079A patent/AT374484B/de not_active IP Right Cessation
- 1979-04-30 AT AT0323179A patent/AT370724B/de not_active IP Right Cessation
- 1979-10-19 CH CH943379A patent/CH624098A5/de not_active IP Right Cessation
- 1979-10-19 CH CH943179A patent/CH621333A5/de not_active IP Right Cessation
- 1979-10-19 CH CH943279A patent/CH621334A5/de not_active IP Right Cessation
1981
- 1981-03-10 NO NO810816A patent/NO149036C/no unknown
1983
- 1983-05-31 DK DK245783A patent/DK155672C/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK159267C (da)	1991-02-18
DK159654C (da)	1991-04-08
AT359085B (de)	1980-10-27
GB1504541A (en)	1978-03-22
DK155520B (da)	1989-04-17
NO146430B (no)	1982-06-21
DE2559989C3 (de)	1981-11-19
JPS514121A (cs)	1976-01-14
DK442477A (da)	1977-10-06
DK155732B (da)	1989-05-08
CS209856B2 (en)	1981-12-31
NL183186C (nl)	1988-08-16
DK155433B (da)	1989-04-10
NO149036B (no)	1983-10-24
AT370724B (de)	1983-04-25
DK442877A (da)	1977-10-06
DK245783A (da)	1983-05-31
DK442577A (da)	1977-10-06
IL47149A (en)	1979-05-31
DK442777A (da)	1977-10-06
AU499173B2 (en)	1979-04-05
DD122377A5 (cs)	1976-10-05
DD125070A5 (cs)	1977-03-30
NL7505075A (nl)	1975-10-31
DK442677A (da)	1977-10-06
ES436986A1 (es)	1977-06-16
FI751256A (cs)	1975-10-30
AU8056475A (en)	1976-11-04
DK158676B (da)	1990-07-02
DK155672C (da)	1989-10-09
SE430164B (sv)	1983-10-24
FI65990B (fi)	1984-04-30
BG26368A3 (bg)	1979-03-15
DK443077A (da)	1977-10-06
DK158676C (da)	1991-01-14
ATA624877A (de)	1980-03-15
SE441356B (sv)	1985-09-30
SU747419A3 (ru)	1980-07-23
CS209857B2 (en)	1981-12-31
DE2518160A1 (de)	1975-11-20
AT374484B (de)	1984-04-25
BE828546A (fr)	1975-08-18
DK245783D0 (da)	1983-05-31
DK442377A (da)	1977-10-06
JPS6012347B2 (ja)	1985-04-01
AT351007B (de)	1979-07-10
ES453304A1 (es)	1977-11-16
AR217236A1 (es)	1980-03-14
DK155672B (da)	1989-05-01
NO810816L (no)	1975-10-30
NO146430C (no)	1982-09-29
CS209858B2 (en)	1981-12-31
FR2279388A1 (fr)	1976-02-20
ATA323179A (de)	1982-09-15
ATA624777A (de)	1980-03-15
IL47149A0 (en)	1975-06-25
AR218221A1 (es)	1980-05-30
ATA314075A (de)	1980-09-15
CS209855B2 (en)	1981-12-31
EG11847A (en)	1979-06-30
CH624098A5 (cs)	1981-07-15
BG26370A4 (bg)	1979-03-15
CA1051802A (en)	1979-04-03
DK159267B (da)	1990-09-24
ES453306A1 (es)	1977-11-16
SE7812884L (sv)	1978-12-14
DE2559989B1 (de)	1981-02-05
PL111746B1 (en)	1980-09-30
SE7504828L (sv)	1975-10-30
NO751504L (cs)	1975-10-30
DK159654B (da)	1990-11-12
ATA624977A (de)	1978-12-15
BG26517A4 (bg)	1979-04-12
AT361902B (de)	1981-04-10
ATA323079A (de)	1983-09-15
CH617183A5 (cs)	1980-05-14
DK155433C (da)	1989-10-16
NO149036C (no)	1984-02-01
DK155732C (da)	1989-10-02
ES453305A1 (es)	1977-11-16
AT359084B (de)	1980-10-27
CH621333A5 (cs)	1981-01-30
BG26369A4 (bg)	1979-03-15
DK442977A (da)	1977-10-06
AR218222A1 (es)	1980-05-30
FR2279388B1 (cs)	1978-07-28
DE2518160C2 (cs)	1993-05-06
FI65990C (fi)	1984-08-10
DK182875A (da)	1975-10-30
PL111745B1 (en)	1980-09-30
DK155520C (da)	1989-10-16

Publication	Publication Date	Title
DE68928920T2 (de)	1999-07-22	Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE69909794T2 (de)	2004-06-09	Verwendung eines dipeptids für wiederherstellungsprozesse
DE60026826T2 (de)	2007-04-12	Alterungsschutztetrapeptid, dieses enthaltende pharmazeutische zusammensetzungen und seine verwendung
DE2549783A1 (de)	1976-05-20	Triglyceride mit entzuendungshemmender wirkung
CH621334A5 (cs)	1981-01-30
DE69001722T2 (de)	1993-09-23	Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
JPS58131952A (ja)	1983-08-06	新規アミノ酸誘導体の製法
DE3730277C2 (de)	1994-12-08	Salz einer Organogermaniumverbindung und dessen Verwendung
EP0100516B1 (de)	1987-10-14	3-Beta-(3'-(Carboxypropionyloxy))-ursa-9(11),12-dien-28-carbonsäure sowie ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2820794C2 (de)	1980-01-17	Salze der (-Hcis)-l^-Epoxypropylphosphonsäure, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Präparat
DE2234832A1 (de)	1973-04-05	Verfahren zur herstellung von litoralon
DE2752756A1 (de)	1978-06-01	Neue derivate des coenzyms b tief 12 , verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE2038836C3 (de)	1979-12-06	Arzneimittel
DE2706841C2 (cs)	1987-12-10
LU87406A1 (de)	1990-02-28	Tromethamin-salz von 1-methyl-beta-oxo-alpha-(phenylcarbamoyl)-2-pyrrolproprionitril
EP0253293B1 (de)	1990-02-28	Neue Guanidiniumasparaginate
DE2028880A1 (en)	1971-12-16	N-phenyl carbamoyl derivs of 3-beta-phenyl isopropyl-synononimines - - as psycho and cns
DE3706431C2 (cs)	1990-05-17
DE2408372A1 (de)	1974-09-19	Pharmazeutische zubereitungen auf der grundlage von hippursaeurederivaten
DE2515142B2 (de)	1976-11-11	Oral verabfolgbare mittel zur senkung des lipid- und cholesterin- spiegels
US2478984A (en)	1949-08-16	Medicinal preparation containing available calcium and phosphorus
DE2808203A1 (de)	1978-09-14	Arzneimittel, enthaltend p-chlorphenoxyisobuttersaeure-p-chlorphenolester
DE3047487A1 (de)	1982-07-08	"pharmazeutische zubereitung zur behandlung von degenerativen erkrankungen der gelenkknorpel und verfahren zu ihrer verwendung"
DE2411197A1 (de)	1974-09-12	Imidazolderivat
DE2345067A1 (de)	1974-03-21	Mittel zur bekaempfung der schweinedysenterie

Legal Events

Date	Code	Title	Description
1993-12-31	PL	Patent ceased
2024-10-31	PL	Patent ceased